| Delayed
Nasdaq Stockholm 03:18:25 2026-08-18 am EDT |
5-day change | 1st Jan Change | ||
| 0.3930 SEK | +0.51% | |
-0.76% | +11.33% |
Published on 08/18/2026 at 03:07 am EDT
Publicnow
IDL Diagnostics starts partnership with Analyst Group for equity research coverage
18 aug. 2026 09:00:00
IDL Diagnostics announced today that the company is entering into a partnership with Analyst Group for equity research coverage and investor communications. The equity research coverage was previously provided by Redeye Nordic Growth AB.
Analyst Group is an independent research firm focused on Nordic growth companies and will henceforth monitor IDL Diagnostics’ performance through ongoing analyses and report commentary. The company’s interim report for the second quarter of 2026, to be published on August 20, will be the first report covered by Analyst Group.
“We have had a very good partnership with Redeye Nordic Growth AB and would like to express our sincere thanks for their commitment and coverage of IDL Diagnostics. We now look forward to working with Analyst Group to further develop our investor communications and increase our visibility in the capital markets in line with the company’s continued growth,” says Gustav Sten, CEO of IDL Diagnostics.
Analyst Group’s research reports will be published through their own channels and made available to investors in conjunction with report releases and other significant events. Recordings related to report releases will be distributed by Direkt Studios and posted on their YouTube channel as well as on the IDL Diagnostics website.
This change applies solely to equity research coverage and does not affect Redeye Nordic Growth AB’s role as Certified Adviser for IDL Diagnostics.
Contacts
Gustav Sten, CEO
Phone: +46 (0) 8 799 67 67
E-mail: gustav.sten@idldiagnostics.com
About IDL Diagnostics
IDL Diagnostics AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, IDL Diagnostics uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. IDL Diagnostics’ product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. IDL Diagnostics (IDLDX) is listed on Nasdaq First North Growth Market with Redeye Sweden AB as company’s Certified Adviser. For more information; https://www.idldiagnostics.com
Attachments
IDL Diagnostics starts partnership with Analyst Group for equity research coverage
IDL Diagnostics starts partnership with Analyst Group for equity research coverage
Attachments
- Original document
- Permalink
Disclaimer
IDL Diagnostics AB (publ) published this content on August 18, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on August 18, 2026 at 07:06 UTC.
IDL Diagnostics AB (publ), formerly AroCell AB (publ), is a Sweden-based diagnostic Company engaged in the biotechnology and medical diagnostics industry. The Company focuses on research, development, manufacturing, and commercialization of diagnostic and medical technology products. The Company has a broad product portfolio of In Vitro Diagnostics (IVD) tests that deliver clinical information for the detection of disease with indications spanning everything from urological cancers to typhoid fever. IDL Diagnostics AB (publ) develops tests that are clinically useful and economically viable. The Company provides rapid tests, laboratory tests and platform tests that improve decision making and are non-invasive, cost effective, as well as easy to perform.
Select your edition
All financial news and data tailored to specific country editions
